Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”
Abstract
:1. Introduction
Aim and Rationale of the Study
2. Results
2.1. The Uses of DMT in Past and Modern Times
2.2. Legal Aspects
2.3. Google Trends: Infodemiology and Infoveillance
2.3.1. Geographic (Spatial) Mapping
2.3.2. Temporal Mapping
3. Discussion
3.1. Highlights of the Most Important Findings
3.2. Clinical Manifestations and Subjective Experiences
3.3. Adverse Events, Intoxications, and Deaths
3.4. Uses in Modern Medicine and Potentials in Precision (Personalized) Medicine
3.5. Study Limitations
4. Materials and Methods
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Cameron, L.P.; Olson, D.E. Dark Classics in Chemical Neuroscience: N,N-Dimethyltryptamine (DMT). ACS Chem. Neurosci. 2018, 9, 2344–2357. [Google Scholar] [CrossRef] [PubMed]
- Jenkins, T.A.; Nguyen, J.C.D.; Polglaze, K.E.; Bertrand, P.P. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients 2016, 8, 56. [Google Scholar] [CrossRef] [Green Version]
- Cameron, L.P.; Benson, C.J.; DeFelice, B.C.; Fiehn, O.; Olson, D.E. Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents. ACS Chem. Neurosci. 2019, 10, 3261–3270. [Google Scholar] [CrossRef] [Green Version]
- Barker, S.A. N,N-Dimethyltryptamine (DMT), an Endogenous Hallucinogen: Past, Present, and Future Research to Determine Its Role and Function. Front. Neurosci. 2018, 12, 536. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Palamar, J.J.; Martins, S.S.; Su, M.K.; Ompad, D.C. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting. Drug Alcohol Depend. 2015, 156, 112–119. [Google Scholar] [CrossRef] [Green Version]
- Palamar, J.J.; Le, A. Trends in DMT and other tryptamine use among young adults in the United States. Am. J. Addict. 2018, 27, 578–585. [Google Scholar] [CrossRef]
- Khaled, S.M.; Hughes, E.; Bressington, D.; Zolezzi, M.; Radwan, A.; Badnapurkar, A.; Gray, R. The prevalence of novel psychoactive substances (NPS) use in non-clinical populations: A systematic review protocol. Syst. Rev. 2016, 5, 195. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Winstock, A.R.; Maier, L.J.; Zhuparris, A.; Davies, E.; Puljevic, C.; Kuypers, K.P.C.; Ferris, J.A.; Barratt, M.J. Global Drug Survey. 2021. Available online: https://www.globaldrugsurvey.com/ (accessed on 20 November 2022).
- Shen, H.W.; Jiang, X.L.; Winter, J.C.; Yu, A.M. Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr. Drug Metab. 2010, 11, 659–666. [Google Scholar] [CrossRef] [Green Version]
- Uthaug, M.V.; Lancelotta, R.; Szabo, A.; Davis, A.K.; Riba, J.; Ramaekers, J.G. Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: Effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology 2020, 237, 773–785. [Google Scholar] [CrossRef] [Green Version]
- Polito, V.; Liknaitzky, P. The emerging science of microdosing: A systematic review of research on low dose psychedelics (1955–2021) and recommendations for the field. Neurosci. Biobehav. Rev. 2022, 139, 104706. [Google Scholar] [CrossRef]
- Ermakova, A.O.; Dunbar, F.; Rucker, J.; Johnson, M.W. A narrative synthesis of research with 5-MeO-DMT. J. Psychopharmacol. 2022, 36, 273–294. [Google Scholar] [CrossRef] [PubMed]
- Nutt, D.J.; King, L.A.; Nichols, D.E. Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat. Rev. Neurosci. 2013, 14, 577–585. [Google Scholar] [CrossRef] [PubMed]
- Hoshino, T.; Shimodaira, K. Über die synthese des bufotenin-methyl-äthers (5-methoxy-n-dimethyl-tryptamin) und bufotenins (synthesen in der indol-gruppe. xv). Bull. Chem. Soc. Jpn. 1936, 11, 221–224. [Google Scholar] [CrossRef]
- Tyler, V.E.; Gröger, D. Investigation of the alkaloids of amanita species1–II. Amanita. Citrina and Amanita porphyria. Planta Med. 1964, 12, 397–402. [Google Scholar] [CrossRef]
- Erspamer, V.; Vitali, T.; Roseghini, M.; Cei, J.M. 5-Methoxy- and 5-hydroxyindoles in the skin of Bufo alvarius. Biochem. Pharmacol. 1967, 16, 1149–1164. [Google Scholar] [CrossRef] [Green Version]
- Drug Science. 5-MEO-DMT (BUFO) Drugscience.Org.Uk. Drug Science 2021. Available online: https://www.drugscience.org.uk/drug-information/5-meo-dmt/ (accessed on 20 November 2022).
- Hamill, J.; Hallak, J.; Dursun, S.M.; Baker, G. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness. Curr. Neuropharmacol. 2019, 17, 108–128. [Google Scholar] [CrossRef]
- Rossi, G.N.; Guerra, L.T.L.; Baker, G.B.; Dursun, S.M.; Saiz, J.C.B.; Hallak, J.E.C.; dos Santos, R.G. Molecular Pathways of the Therapeutic Effects of Ayahuasca, a Botanical Psychedelic and Potential Rapid-Acting Antidepressant. Biomolecules 2022, 12, 1618. [Google Scholar] [CrossRef]
- Bergwerf, H. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) Molview. Herman Bergwerf. 2014. Available online: https://molview.org/ (accessed on 20 November 2022).
- Lopez, N. An Exploration of Linguistic Relativity Theory for Consideration of Terence McKenna’s “Stoned Ape Theory” on the Origins of Consciousness and Language: Implications for Language Pedagogy. J. Conscious Evol. 2020, 16, 6. [Google Scholar]
- Lieberman, P. FOXP2 and Human Cognition. Cell 2009, 137, 800–802. [Google Scholar] [CrossRef] [Green Version]
- Lakatos, L.; Janka, Z. Az emberi agy és intelligencia evolúciója [Evolution of human brain and intelligence]. Ideggyogy. Szle. 2008, 61, 220–229. [Google Scholar]
- Reckweg, J.T.; Uthaug, M.V.; Szabo, A.; Davis, A.K.; Lancelotta, R.; Mason, N.L.; Ramaekers, J.G. The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J. Neurochem. 2022, 162, 128–146. [Google Scholar] [CrossRef]
- Eckernäs, E.; Timmermann, C.; Carhart-Harris, R.; Röshammar, D.; Ashton, M. Population pharmacokinetic/pharmacodynamic modeling of the psychedelic experience induced by N,N-dimethyltryptamine—Implications for dose considerations. Clin. Transl. Sci. 2022, 15, 2928–2937. [Google Scholar] [CrossRef] [PubMed]
- De Rios, M.D.; Grob, C. Ritual Uses of Psychoactive Drugs. In Encyclopedia of Psychopharmacology; Stolerman, I.P., Ed.; Springer: Berlin/Heidelberg, Germany, 2010. [Google Scholar]
- Motyka, M.; Marcinkowski, J.T. Nowe metody odurzania się. Cz. III. Roślinne halucynogeny: Bieluń i ayahuasca. [New methods of intoxication. Part III. Plant-based hallucinogens: Whitebait and ayahuasca]. Probl. Hig. Epidemiol. 2014, 4, 806–815. [Google Scholar]
- Wierucka, A. Dawne sposoby leczenia i ich pozostałości w kulturach Quichua i Shuar znad rzeki Napo w Ekwadorze. [ Ancient healing modalities and their remnants in Quichua and Shuar cultures from the Napo River in Ecuador]. In Re-Wizje Ameryki Południowej: Studenckie Badania Naukowe Ekwador 2009; Wierucka, A., Ed.; Wydawnictwo Uniwersytetu Gdańskiego: Sopot, Poland, 2011. [Google Scholar]
- Weil, A.T.; Davis, W. Bufo alvarius: A potent hallucinogen of animal origin. J. Ethnopharmacol. 1994, 41, 1–8. [Google Scholar] [CrossRef]
- Torres, C.M.; Repke, D.B. Anadenanthera: Visionary Plant of Ancient South America; Haworth Herbal Press: New York, NY, USA, 2006. [Google Scholar]
- Riba, J.; Rodríguez-Fornells, A.; Urbano, G.; Morte, A.; Antonijoan, R.; Montero, M.; Callaway, J.C.; Barbanoj, M.J. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology 2001, 154, 85–95. [Google Scholar] [CrossRef] [PubMed]
- Tupper, K.W. The globalization of Ayahuasca: Harm reduction or benefit maximization? Int. J. Drug Policy 2008, 19, 297–303. [Google Scholar] [CrossRef] [PubMed]
- Gearin, A.K.; Luna, L.E.; Mendive, F.; Leonti, M.; Ferrante, C.; Menghini, L.; Politi, M. Editorial: Beyond the Pharmacology of Psychoactive Plant Medicines and Drugs: Pros and Cons of the Role of Rituals and Set and Setting. Front. Pharmacol. 2021, 12, 804254. [Google Scholar] [CrossRef] [PubMed]
- Hartogsohn, I. Set and Setting in the Santo Daime. Front. Pharmacol. 2021, 12, 651037. [Google Scholar] [CrossRef]
- Gonzalez, D.; Cantillo, J.; Perez, I.; Carvalho, M.; Aronovich, A.; Farre, M.; Feilding, A.; Obiols, J.E.; Bouso, J.C. The Shipibo Ceremonial Use of Ayahuasca to Promote Well-Being: An Observational Study. Front. Pharmacol. 2021, 12, 623923. [Google Scholar] [CrossRef] [PubMed]
- Perkins, D.; Schubert, V.; Simonová, H.; Tófoli, L.F.; Bouso, J.C.; Horák, M.; Galvão-Coelho, N.L.; Sarris, J. Influence of Context and Setting on the Mental Health and Well-being Outcomes of Ayahuasca Drinkers: Results of a Large International Survey. Front. Pharmacol. 2021, 12, 623979. [Google Scholar] [CrossRef] [PubMed]
- Dos Santos, R.G.; Bouso, J.C.; Rocha, J.M.; Rossi, G.N.; Hallak, J.E. The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Manag. Health Policy 2021, 14, 901–910. [Google Scholar] [CrossRef]
- Jędrzejko, K.; Kaczmarczyk, P. Banisteria Ayahuasca–obrzędowa i lecznicza roślina plemion amazońskich. [Banisteria Ayahuasca—A ceremonial and medicinal plant of Amazonian tribes]. Gaz. Farm. 2010, 12, 30–32. [Google Scholar]
- Jacob, M.S.; Presti, D.E. Endogenous psychoactive tryptamines reconsidered: An anxiolytic role for dimethyltryptamine. Med. Hypotheses 2005, 64, 930–937. [Google Scholar] [CrossRef]
- Jakubowska, I.; Choma, J. Właściwości i oznaczanie substancji o działaniu psychoaktywnym. [Properties and determination of substances with a psychoactive effect]. Biul. WAT 2013, 62, 123–143. [Google Scholar]
- Szukalski, B.; Błachut, D.; Bykas-Strękowska, M. Dopalacze–nowe psychoaktywne preparaty objęte kontrolą (nowelizacja ustawy o przeciwdziałaniu narkomanii). [Legal highs—New psychoactive preparations under control (amendment of the Act on Counteracting Drug Addiction)]. Probl. Krym. 2009, 265, 19–32. [Google Scholar]
- Kavenská, V.; Simonová, H. Ayahuasca Tourism: Participants in Shamanic Rituals and their Personality Styles, Motivation, Benefits and Risks. J. Psychoact. Drugs 2015, 47, 351–359. [Google Scholar] [CrossRef]
- Winkelman, M. Introduction: Evidence for entheogen use in prehistory and world religions. J. Psychedelic Stud. 2019, 3, 43–62. [Google Scholar] [CrossRef]
- Motyka, M. Drug tourism. Hygeia Public Health 2016, 51, 31–38. [Google Scholar]
- Baghramian, A. The Magic of Shamanism: The Healing Power of the Shamanic Journey; Book Guild Publishing: London, UK, 2007. [Google Scholar]
- Google Trends. Available online: https://trends.google.com/trends/ (accessed on 18 November 2022).
- British Broadcasting Corporation. Porn Star Nacho Vidal Held in Spain after Man Dies in Toad-Venom Ritual. BBC News. 2020. Available online: https://www.bbc.com/news/world-europe-52920291 (accessed on 20 November 2022).
- Carbonaro, T.M.; Gatch, M.B. Neuropharmacology of N,N-dimethyltryptamine. Brain Res. Bull. 2016, 126, 74–88. [Google Scholar] [CrossRef] [Green Version]
- Pic-Taylor, A.; da Motta, L.G.; de Morais, J.A.; Junior, W.M.; Santos Ade, F.; Campos, L.A.; Mortari, M.R.; von Zuben, M.V.; Caldas, E.D. Behavioural and neurotoxic effects of ayahuasca infusion (Banisteriopsis caapi and Psychotria viridis) in female Wistar rat. Behav Process. 2015, 118, 102–110. [Google Scholar] [CrossRef]
- Griffiths, R.R.; Hurwitz, E.S.; Davis, A.K.; Johnson, M.W.; Jesse, R. Survey of subjective “God encounter experiences”: Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. PLoS ONE 2019, 14, e0214377. [Google Scholar] [CrossRef] [Green Version]
- Metzner, R. Ayahuasca. Święte Pnącze Duchów; Okultura: Warszawa, Poland, 2010. [Google Scholar]
- Davis, A.K.; Averill, L.A.; Sepeda, N.D.; Barsuglia, J.P.; Amoroso, T. Psychedelic Treatment for Trauma-Related Psychological and Cognitive Impairment among US Special Operations Forces Veterans. Chronic Stress 2020, 4, 2470547020939564. [Google Scholar] [CrossRef]
- Uthaug, M.V.; Lancelotta, R.; Ortiz Bernal, A.M.; Davis, A.K.; Ramaekers, J.G. A comparison of reactivation experiences following vaporization and intramuscular injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. J. Psychedelic Stud. 2020, 4, 104–113. [Google Scholar] [CrossRef] [Green Version]
- Bouso, J.C.; Andión, Ó.; Sarris, J.J.; Scheidegger, M.; Tófoli, L.F.; Opaleye, E.S.; Schubert, V.; Perkins, D. Adverse effects of ayahuasca: Results from the Global Ayahuasca Survey. PLoS Glob. Public Health 2022, 2, e0000438. [Google Scholar] [CrossRef] [PubMed]
- Hurd, R. The Possibilities and Risks of Ayahuasca as a Sacred Pilgrimage. Matador Network. 2022. Available online: http://matadornetwork.com/bnt/the-possibilities-and-risks-of-ayahuasca-as-a-sacred-pilgrimage/ (accessed on 8 December 2022).
- Bilhimer, M.H.; Schult, R.F.; Higgs, K.V.; Wiegand, T.J.; Gorodetsky, R.M.; Acquisto, N.M. Acute Intoxication following Dimethyltryptamine Ingestion. Case Rep. Emerg. Med. 2018, 2018, 3452691. [Google Scholar] [CrossRef] [PubMed]
- Sklerov, J.; Levine, B.; Moore, K.A.; King, T.; Fowler, D. A fatal intoxication following the ingestion of 5-methoxy-N,N-dimethyltryptamine in an ayahuasca preparation. J. Anal. Toxicol. 2005, 29, 838–841. [Google Scholar] [CrossRef] [Green Version]
- Nižnanský, L.; Nižnanská, Ž.; Kuruc, R.; Szórádová, A.; Šikuta, J.; Zummerová, A. Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects. J. Clin. Med. 2022, 11, 1147. [Google Scholar] [CrossRef]
- Brito-da-Costa, A.M.; Dias-da-Silva, D.; Gomes, N.G.M.; Dinis-Oliveira, R.J.; Madureira-Carvalho, Á. Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,N-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact. Pharmaceuticals 2020, 13, 334. [Google Scholar] [CrossRef]
- Dos Santos, R.G.; Bouso, J.C.; Hallak, J.E.C. Ayahuasca, dimethyltryptamine, and psychosis: A systematic review of human studies. Ther. Adv. Psychopharmacol. 2017, 7, 141–157. [Google Scholar] [CrossRef] [Green Version]
- Więckiewicz, G.; Stokłosa, I.; Piegza, M.; Gorczyca, P.; Pudlo, R. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review. Pharmaceuticals 2021, 14, 793. [Google Scholar] [CrossRef]
- Davis, A.K.; Barsuglia, J.P.; Lancelotta, R.; Grant, R.M.; Renn, E. The epidemiology of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J. Psychopharmacol. 2018, 32, 779–792. [Google Scholar] [CrossRef] [PubMed]
- Johansen, P.Ø.; Krebs, T.S. Psychedelics not linked to mental health problems or suicidal behavior: A population study. J. Psychopharmacol. 2015, 29, 270–279. [Google Scholar] [CrossRef]
- Ona, G.; Kohek, M.; Massaguer, T.; Gomariz, A.; Jiménez, D.F.; Dos Santos, R.G.; Hallak, J.E.C.; Alcázar-Córcoles, M.Á.; Bouso, J.C. Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users. J. Psychoact. Drugs 2019, 51, 135–145. [Google Scholar] [CrossRef] [PubMed]
- De Frias, U.A.; Costa, M.C.; Takahashi, J.A.; Oki, Y. Banisteriopsis Species: A source of bioactive of potential medical application. Int. J. Biotechnol. Wellness Ind. 2012, 1, 163–171. [Google Scholar] [CrossRef]
- Mabit, J. Ayahuasca in the Treatment of Addictions. In Psychedelic Medicine: New Evidence for Hallucinogic Substances as Treatments; Roberts, T.B., Winkelman, M.J., Eds., Eds.; Praeger: Westport, CT, USA, 2007; Volume 2, pp. 87–103. [Google Scholar]
- Liester, M.B.; Prickett, J.I. Hypotheses regarding the mechanisms of ayahuasca in the treatment of addictions. J. Psychoact. Drugs 2012, 44, 200–208. [Google Scholar] [CrossRef] [PubMed]
- Schenberg, E.E. Ayahuasca and cancer treatment. SAGE Open Med. 2013, 1, 2050312113508389. [Google Scholar] [CrossRef]
- Hendricks, P.S.; Thorne, C.B.; Clark, C.B.; Coombs, D.W.; Johnson, M.W. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. J. Psychopharmacol. 2015, 29, 280–288. [Google Scholar] [CrossRef]
- Uthaug, M.V.; Lancelotta, R.; van Oorsouw, K.; Kuypers, K.P.C.; Mason, N.; Rak, J.; Šuláková, A.; Jurok, R.; Maryška, M.; Kuchař, M.; et al. A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology 2019, 236, 2653–2666. [Google Scholar] [CrossRef] [Green Version]
- MedlinePlus. What Is Precision Medicine? Medlineplus Genetics. MedlinePlus. U.S. National Library of Medicine. Available online: https://medlineplus.gov/genetics/understanding/precisionmedicine/definition/ (accessed on 8 December 2022).
- U.S. Food and Drug Administration. Precision Medicine. 2018. Available online: https://www.fda.gov/medical-devices/in-vitro-diagnostics/precision-medicine (accessed on 8 December 2022).
- U.S. Centers for Disease Control and Prevention. Precision Health: Improving Health for Each of Us and All of Us. 2022. Available online: https://www.cdc.gov/genomics/about/precision_med.htm (accessed on 8 December 2022).
- Davis, A.K.; So, S.; Lancelotta, R.; Barsuglia, J.P.; Griffiths, R.R. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am. J. Drug Alcohol Abus. 2019, 45, 161–169. [Google Scholar] [CrossRef]
- Dakic, V.; Minardi Nascimento, J.; Costa Sartore, R.; Maciel, R.M.; de Araujo, D.B.; Ribeiro, S.; Martins-de-Souza, D.; Rehen, S.K. Short term changes in the proteome of human cerebral organoids induced by 5-MeO-DMT. Sci. Rep. 2017, 7, 12863. [Google Scholar] [CrossRef] [Green Version]
- Ezra, P.J.; Misra, S.; Agrawal, A.; Oluranti, J.; Maskeliunas, R.; Damasevicius, R. Secured communication using virtual private network (VPN). Cyber Secur. Digit. Forensics 2022, 73, 309–319. [Google Scholar] [CrossRef]
- Al-Imam, A.; AbdulMajeed, B.A. The NPS Phenomenon and the Deep Web: Internet Snapshots of the Darknet and Potentials of Data Mining. Glob. J. Health Sci. 2017, 9, 86–101. [Google Scholar] [CrossRef] [Green Version]
- Al-Imam, A.; AbdulMajeed, B.A. The Most Popular Chemical Categories of NPS in Four Leading Countries of the Developed World: An Integrative Analysis of Trends Databases, Surface Web, and the Deep Web. Glob. J. Health Sci. 2017, 9, 27–39. [Google Scholar] [CrossRef] [Green Version]
- Al-Imam, A.; AbdulMajeed, B.A. The NPS Phenomenon and the Deep Web: Trends Analyses and Internet Snapshots. Glob. J. Health Sci. 2017, 9, 71–85. [Google Scholar] [CrossRef] [Green Version]
- Al-Imam, A. Monitoring and Analysis of Novel Psychoactive Substances in Trends Databases, Surface Web and the Deep Web, with Special Interest and Geo-Mapping of the Middle East. Master’s Thesis, University of Hertfordshire, Hertfordshire, UK, 2017. [Google Scholar] [CrossRef]
- Vaughan, L.; Chen, Y. Data mining from web search queries: A comparison of google trends and baidu index. J. Assoc. Inf. Sci. Technol. 2015, 66, 13–22. [Google Scholar] [CrossRef]
- Al-Imam, A.; Motyka, M.A.; Witulska, Z.; Younus, M.; Michalak, M. Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland. Int. J. Environ. Res. Public Health 2022, 19, 6619. [Google Scholar] [CrossRef] [PubMed]
Search Term | p-Value | Intercept | β | 95% Confidence Interval | |
---|---|---|---|---|---|
N,N-dimethyltryptamine | 0.283 | 72.38 | 0.02 | −0.02 | 0.07 |
5-MeO-DMT | <0.001 | 30.75 | 0.37 | 0.32 | 0.41 |
Colorado River toad | <0.001 | 2.92 | 0.17 | 0.13 | 0.21 |
Sonoran Desert toad | <0.001 | 5.15 | 0.23 | 0.17 | 0.30 |
5-methoxy-N,N-dimethyltryptamine | 0.747 | 6.43 | 0.02 | −0.09 | 0.12 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Al-Imam, A.; Motyka, M.A.; Hoffmann, B.; Magowska, A.; Michalak, M. Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”. Pharmaceuticals 2023, 16, 831. https://doi.org/10.3390/ph16060831
Al-Imam A, Motyka MA, Hoffmann B, Magowska A, Michalak M. Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”. Pharmaceuticals. 2023; 16(6):831. https://doi.org/10.3390/ph16060831
Chicago/Turabian StyleAl-Imam, Ahmed, Marek A. Motyka, Beata Hoffmann, Anita Magowska, and Michal Michalak. 2023. "Infoveillance and Critical Analysis of the Systematically Reviewed Literature on Dimethyltryptamine and the “God Molecule”" Pharmaceuticals 16, no. 6: 831. https://doi.org/10.3390/ph16060831